Business Strategies

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

Curaleaf appoints president, marketing, digital, and brand leads; Lemon Perfect adds marketing, strategy chiefs; Nature Made, HelloFresh stir up ‘Gut Friendly’ recipes; and Thrive serves promotions for USA Pickleball.

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Roberto Khoury, Perrigo’s international lead for a year, moves to CCO while his counterpart for the Americas region appointed in September 2023, Catherine "Triona" Schmelter, is leaving with her post eliminated in the firm’s changes.

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment